Logo image of DXCM

DEXCOM INC (DXCM) Stock Fundamental Analysis

USA - NASDAQ:DXCM - US2521311074 - Common Stock

70.58 USD
+0.83 (+1.19%)
Last: 10/22/2025, 2:47:10 PM
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to DXCM. DXCM was compared to 190 industry peers in the Health Care Equipment & Supplies industry. While DXCM belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. DXCM is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings could make DXCM a good candidate for growth investing.


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

In the past year DXCM was profitable.
In the past year DXCM had a positive cash flow from operations.
DXCM had positive earnings in each of the past 5 years.
In the past 5 years DXCM always reported a positive cash flow from operatings.
DXCM Yearly Net Income VS EBIT VS OCF VS FCFDXCM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

1.2 Ratios

With an excellent Return On Assets value of 7.80%, DXCM belongs to the best of the industry, outperforming 91.05% of the companies in the same industry.
DXCM's Return On Equity of 22.21% is amongst the best of the industry. DXCM outperforms 94.21% of its industry peers.
DXCM's Return On Invested Capital of 14.52% is amongst the best of the industry. DXCM outperforms 94.21% of its industry peers.
The Average Return On Invested Capital over the past 3 years for DXCM is above the industry average of 8.88%.
The 3 year average ROIC (11.25%) for DXCM is below the current ROIC(14.52%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 7.8%
ROE 22.21%
ROIC 14.52%
ROA(3y)7.95%
ROA(5y)8.21%
ROE(3y)23.2%
ROE(5y)22.06%
ROIC(3y)11.25%
ROIC(5y)9.23%
DXCM Yearly ROA, ROE, ROICDXCM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20 30

1.3 Margins

The Profit Margin of DXCM (13.29%) is better than 89.47% of its industry peers.
DXCM's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 17.22%, DXCM belongs to the best of the industry, outperforming 87.37% of the companies in the same industry.
DXCM's Operating Margin has improved in the last couple of years.
The Gross Margin of DXCM (60.01%) is comparable to the rest of the industry.
DXCM's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 17.22%
PM (TTM) 13.29%
GM 60.01%
OM growth 3Y10.52%
OM growth 5Y8.87%
PM growth 3Y17.27%
PM growth 5Y15.84%
GM growth 3Y-3.98%
GM growth 5Y-0.72%
DXCM Yearly Profit, Operating, Gross MarginsDXCM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

5

2. Health

2.1 Basic Checks

DXCM has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, DXCM has more shares outstanding
The number of shares outstanding for DXCM has been increased compared to 5 years ago.
The debt/assets ratio for DXCM has been reduced compared to a year ago.
DXCM Yearly Shares OutstandingDXCM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
DXCM Yearly Total Debt VS Total AssetsDXCM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

DXCM has an Altman-Z score of 5.01. This indicates that DXCM is financially healthy and has little risk of bankruptcy at the moment.
DXCM has a Altman-Z score of 5.01. This is in the better half of the industry: DXCM outperforms 77.37% of its industry peers.
DXCM has a debt to FCF ratio of 4.38. This is a neutral value as DXCM would need 4.38 years to pay back of all of its debts.
DXCM has a Debt to FCF ratio of 4.38. This is amongst the best in the industry. DXCM outperforms 80.53% of its industry peers.
DXCM has a Debt/Equity ratio of 0.50. This is a neutral value indicating DXCM is somewhat dependend on debt financing.
DXCM's Debt to Equity ratio of 0.50 is in line compared to the rest of the industry. DXCM outperforms 42.11% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.5
Debt/FCF 4.38
Altman-Z 5.01
ROIC/WACC1.83
WACC7.95%
DXCM Yearly LT Debt VS Equity VS FCFDXCM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.3 Liquidity

DXCM has a Current Ratio of 1.52. This is a normal value and indicates that DXCM is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.52, DXCM is not doing good in the industry: 73.68% of the companies in the same industry are doing better.
DXCM has a Quick Ratio of 1.35. This is a normal value and indicates that DXCM is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of DXCM (1.35) is worse than 64.21% of its industry peers.
Industry RankSector Rank
Current Ratio 1.52
Quick Ratio 1.35
DXCM Yearly Current Assets VS Current LiabilitesDXCM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

7

3. Growth

3.1 Past

DXCM shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.86%.
DXCM shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 29.25% yearly.
The Revenue has grown by 9.30% in the past year. This is quite good.
Measured over the past years, DXCM shows a very strong growth in Revenue. The Revenue has been growing by 22.27% on average per year.
EPS 1Y (TTM)-2.86%
EPS 3Y35.38%
EPS 5Y29.25%
EPS Q2Q%11.63%
Revenue 1Y (TTM)9.3%
Revenue growth 3Y18.1%
Revenue growth 5Y22.27%
Sales Q2Q%15.21%

3.2 Future

DXCM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.60% yearly.
The Revenue is expected to grow by 13.90% on average over the next years. This is quite good.
EPS Next Y26.84%
EPS Next 2Y26.2%
EPS Next 3Y24.65%
EPS Next 5Y22.6%
Revenue Next Year14.99%
Revenue Next 2Y15.17%
Revenue Next 3Y14.81%
Revenue Next 5Y13.9%

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
DXCM Yearly Revenue VS EstimatesDXCM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B
DXCM Yearly EPS VS EstimatesDXCM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 2 3 4 5

5

4. Valuation

4.1 Price/Earnings Ratio

DXCM is valuated quite expensively with a Price/Earnings ratio of 41.52.
69.47% of the companies in the same industry are more expensive than DXCM, based on the Price/Earnings ratio.
DXCM is valuated rather expensively when we compare the Price/Earnings ratio to 27.77, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 26.86 indicates a quite expensive valuation of DXCM.
Based on the Price/Forward Earnings ratio, DXCM is valued a bit cheaper than 73.68% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.23, DXCM is valued at the same level.
Industry RankSector Rank
PE 41.52
Fwd PE 26.86
DXCM Price Earnings VS Forward Price EarningsDXCM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, DXCM is valued a bit cheaper than the industry average as 72.63% of the companies are valued more expensively.
76.84% of the companies in the same industry are more expensive than DXCM, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 48.49
EV/EBITDA 25.75
DXCM Per share dataDXCM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
DXCM has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as DXCM's earnings are expected to grow with 24.65% in the coming years.
PEG (NY)1.55
PEG (5Y)1.42
EPS Next 2Y26.2%
EPS Next 3Y24.65%

0

5. Dividend

5.1 Amount

No dividends for DXCM!.
Industry RankSector Rank
Dividend Yield N/A

DEXCOM INC

NASDAQ:DXCM (10/22/2025, 2:47:10 PM)

70.58

+0.83 (+1.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)07-30 2025-07-30/amc
Earnings (Next)10-30 2025-10-30/amc
Inst Owners97.73%
Inst Owner Change-0.28%
Ins Owners0.19%
Ins Owner Change2.47%
Market Cap27.68B
Revenue(TTM)4.30B
Net Income(TTM)571.50M
Analysts84.57
Price Target104.5 (48.06%)
Short Float %3.37%
Short Ratio2.66
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.34%
Min EPS beat(2)-4.09%
Max EPS beat(2)6.77%
EPS beat(4)2
Avg EPS beat(4)-1.87%
Min EPS beat(4)-11.66%
Max EPS beat(4)6.77%
EPS beat(8)6
Avg EPS beat(8)9.43%
EPS beat(12)10
Avg EPS beat(12)14.38%
EPS beat(16)11
Avg EPS beat(16)8.49%
Revenue beat(2)1
Avg Revenue beat(2)0.34%
Min Revenue beat(2)-0.19%
Max Revenue beat(2)0.88%
Revenue beat(4)1
Avg Revenue beat(4)-0.54%
Min Revenue beat(4)-1.66%
Max Revenue beat(4)0.88%
Revenue beat(8)2
Avg Revenue beat(8)-0.78%
Revenue beat(12)5
Avg Revenue beat(12)-0.39%
Revenue beat(16)6
Avg Revenue beat(16)-0.42%
PT rev (1m)-0.85%
PT rev (3m)2.36%
EPS NQ rev (1m)0.42%
EPS NQ rev (3m)0.28%
EPS NY rev (1m)0.14%
EPS NY rev (3m)1.07%
Revenue NQ rev (1m)0.08%
Revenue NQ rev (3m)0.67%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)0.23%
Valuation
Industry RankSector Rank
PE 41.52
Fwd PE 26.86
P/S 6.44
P/FCF 48.49
P/OCF 28.02
P/B 10.76
P/tB 11.24
EV/EBITDA 25.75
EPS(TTM)1.7
EY2.41%
EPS(NY)2.63
Fwd EY3.72%
FCF(TTM)1.46
FCFY2.06%
OCF(TTM)2.52
OCFY3.57%
SpS10.97
BVpS6.56
TBVpS6.28
PEG (NY)1.55
PEG (5Y)1.42
Graham Number15.84
Profitability
Industry RankSector Rank
ROA 7.8%
ROE 22.21%
ROCE 18.43%
ROIC 14.52%
ROICexc 53.56%
ROICexgc 59.66%
OM 17.22%
PM (TTM) 13.29%
GM 60.01%
FCFM 13.27%
ROA(3y)7.95%
ROA(5y)8.21%
ROE(3y)23.2%
ROE(5y)22.06%
ROIC(3y)11.25%
ROIC(5y)9.23%
ROICexc(3y)35.45%
ROICexc(5y)29.66%
ROICexgc(3y)40.94%
ROICexgc(5y)33.19%
ROCE(3y)14.28%
ROCE(5y)11.73%
ROICexgc growth 3Y55.18%
ROICexgc growth 5Y18.96%
ROICexc growth 3Y50.14%
ROICexc growth 5Y16.58%
OM growth 3Y10.52%
OM growth 5Y8.87%
PM growth 3Y17.27%
PM growth 5Y15.84%
GM growth 3Y-3.98%
GM growth 5Y-0.72%
F-Score6
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0.5
Debt/FCF 4.38
Debt/EBITDA 1.33
Cap/Depr 176.58%
Cap/Sales 9.69%
Interest Coverage 250
Cash Conversion 101.12%
Profit Quality 99.88%
Current Ratio 1.52
Quick Ratio 1.35
Altman-Z 5.01
F-Score6
WACC7.95%
ROIC/WACC1.83
Cap/Depr(3y)175.34%
Cap/Depr(5y)240.83%
Cap/Sales(3y)9.32%
Cap/Sales(5y)10.84%
Profit Quality(3y)97.76%
Profit Quality(5y)73.64%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.86%
EPS 3Y35.38%
EPS 5Y29.25%
EPS Q2Q%11.63%
EPS Next Y26.84%
EPS Next 2Y26.2%
EPS Next 3Y24.65%
EPS Next 5Y22.6%
Revenue 1Y (TTM)9.3%
Revenue growth 3Y18.1%
Revenue growth 5Y22.27%
Sales Q2Q%15.21%
Revenue Next Year14.99%
Revenue Next 2Y15.17%
Revenue Next 3Y14.81%
Revenue Next 5Y13.9%
EBIT growth 1Y6.1%
EBIT growth 3Y30.52%
EBIT growth 5Y33.11%
EBIT Next Year77.25%
EBIT Next 3Y38.83%
EBIT Next 5Y31.4%
FCF growth 1Y22.49%
FCF growth 3Y127.88%
FCF growth 5Y36.21%
OCF growth 1Y28.04%
OCF growth 3Y30.77%
OCF growth 5Y25.76%